(b)ARCHER1050 was a phase III trial comparing dacomitinib with gefitinib in stage IV NSCLC patients who have EGFR mutation (exon 19 deletion or L858R mutation) and PS of 0–1. This evidence concerns the gene EGFR and non-small cell lung carcinoma.